Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 90 clinical trials
Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell

bone marrow failure
shortening fraction
chronic leukemias
graft versus host disease
lymphoma
  • 130 views
  • 17 Nov, 2021
  • 1 location
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T

hematologic malignancy
bone marrow transplant
cancer
graft-versus-host disease
graft versus host disease
  • 0 views
  • 10 Apr, 2022
  • 1 location
Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT

choice Best Available Therapy (BAT) in allogeneic hematopoietic stem cell transplant recipients with Grades II-IV steroid refractory acute graft vs. host disease in the second part of the study. Patients

  • 0 views
  • 10 Oct, 2021
  • 6 locations
IS-free Treg HaploHCT

myelodysplastic syndromes (MDS) receiving a haploidentical donor allogeneic hematopoietic stem cell transplant (HSCT). The names of the study interventions involved in this study are:

cyclophosphamide
fludarabine
gilbert's syndrome
myelodysplastic syndromes
cell transplantation
  • 0 views
  • 08 Jul, 2022
  • 1 location
Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients

High dose chemotherapy and radiation used as preparative regimens in patients undergoing an allogeneic hematopoietic stem cell transplant (HSCT) disrupts intestinal homeostasis by damaging the

bone marrow transplant
allogeneic hematopoietic stem cell transplant
acute graft-versus-host disease
graft versus host disease
  • 0 views
  • 13 Jun, 2022
  • 1 location
Phase II Study of a Geriatric Assessment-Driven, Risk-Adapted Allogeneic Hematopoietic Cell Transplant Strategy for Older Patients With Myeloid Malignancies

, ,myelodysplastic syndromes, myeloproliferative neoplasms, or related blood disorders who are going to receive chemotherapy or another treatment to prepare the body for an allogeneic hematopoietic stem cell

chronic myeloid leukemia
chronic myelomonocytic leukemia
myelomonocytic leukemia
myeloid leukemia
transplant conditioning
  • 0 views
  • 15 Sep, 2022
  • 7 locations
Combination Chemotherapy Total Body Irradiation and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis

This pilot phase I trial studies the side effects of combination chemotherapy, total body irradiation, and donor blood stem cell transplant in treating patients with secondary myelofibrosis. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them …

  • 34 views
  • 27 Aug, 2021
  • 2 locations
Post-Transplant Bendamustine (PT-BEN) for GVHD Prophylaxis

This phase I/II trial studies the side effects and best dose of bendamustine when given with or without cyclophosphamide in preventing graft versus host disease (GVHD) in patients undergoing stem cell transplant. Drugs used in chemotherapy, such as bendamustine and cyclophosphamide, work in different ways to stop the growth of …

cyclophosphamide
fludarabine
mycophenolate
total body irradiation
hematologic malignancy
  • 6 views
  • 17 Sep, 2022
  • 1 location
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) and are planning to have an allogeneic hematopoietic stem cell transplant ("bone marrow transplant"). The goal of this research study is to (1

azacitidine
gilbert's syndrome
decitabine
bone marrow transplant
cancer
  • 34 views
  • 24 Jul, 2022
  • 1 location
Phase I/II Study of Sorafenib Added to Busulfan and Fludarabine Conditioning Regimen in Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation

This phase I/II trial studies the best dose of sorafenib when given together with busulfan and fludarabine in treating patients with acute myeloid leukemia that has come back or does not respond to treatment and who are undergoing donor stem cell transplant. Sorafenib may stop the growth of cancer cells …

cyclophosphamide
fludarabine
mycophenolate mofetil
cell transplantation
cancer
  • 13 views
  • 16 Sep, 2022
  • 1 location